The antimycotic action and tolerance to
terconazole in patients with vaginal
candidiasis, were evaluated in a blind study. The medication was given in vaginal ovules (VO)240 mg, one dose per day, and 80 mg one daily dose for three days; as compared to chlotrimazole, VO 200 mg, daily dose for three days. The patients presented with vaginal
candidiasis demonstrated by Nickerson culture medium. Sixty patients were studied in three equivalent groups. The mates of patients treated with
terconazole had no treatment; and the mates of patients treated with chlotrimazole received urinary acidifying medication. Symptomatology and mycologic findings were evaluated
at 10 and 28 days post treatment. Mycological cure rates
at 10 days were: 90 per cent for the
terconazole group, 240 mg, one dose; and 95 per cent for patients with
terconazole, 80 mg, daily dose for three days; or chlotrimazole, 200 mg, daily dose for three days. Twenty eight days post-treatment, laboratory tests were positive again: 50%, 40% and 15%, respectively. Recidive in patients treated with
terconazole, is explained by lack of treatment in mates. In conclusion,
terconazole offers a high percentage of clinical and mycological cure in vaginal
candidiasis, and it is indispensable treatment for the mate, in order to avoid recidives.